Pugh, S.A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J.W., O'Reilly, D.A., Siriwardena, A.K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T. F., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O.J., Cunningham, D., Maughan, T.S., Bridgewater, J,A. and Primrose, J.N., 2016. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 115 (4), 420 - 424.
Full text available as:
Pugh et al.pdf - Published Version
Restricted to Repository staff only until 19 July 2017.
Available under License Creative Commons Attribution Non-commercial Share Alike.
BACKGROUND: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome. METHODS: A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and treatment of progressive disease were obtained for the 109 (CT n=48, CT and CTX n=61) patients with progressive disease at the cut-off date for analysis of November 2012. RESULTS: The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P=0.04). Further treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based. Twenty-two patients, 11 in each arm, received CTX as a further line agent. CONCLUSIONS: Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease control following liver surgery.
|Uncontrolled Keywords:||colorectal liver metastases; colorectal cancer; cetuximab; epidermal growth factor inhibition; chemotherapy; liver resection; progressive disease; cancer research UK|
|Group:||Faculty of Health & Social Sciences|
|Deposited By:||Unnamed user with email symplectic@symplectic|
|Deposited On:||20 Oct 2016 15:06|
|Last Modified:||20 Oct 2016 15:10|
Downloads per month over past year
|Repository Staff Only -|